Neuroscience Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
PLoS One. 2012;7(7):e40038. doi: 10.1371/journal.pone.0040038. Epub 2012 Jul 6.
BACKGROUND & AIMS: Gastrointestinal peptides are increasingly being linked to processes controlling the maintenance of bone mass. Peptide YY (PYY), a gut-derived satiety peptide of the neuropeptide Y family, is upregulated in some states that also display low bone mass. Importantly, PYY has high affinity for Y-receptors, particularly Y1R and Y2R, which are known to regulate bone mass. Anorexic conditions and bariatric surgery for obesity influence circulating levels of PYY and have a negative impact on bone mass, but the precise mechanism behind this is unclear. We thus examined whether alterations in PYY expression affect bone mass.
Bone microstructure and cellular activity were analyzed in germline PYY knockout and conditional adult-onset PYY over-expressing mice at lumbar and femoral sites using histomorphometry and micro-computed tomography.
PYY displayed a negative relationship with osteoblast activity. Male and female PYY knockout mice showed enhanced osteoblast activity, with greater cancellous bone mass. Conversely, PYY over-expression lowered osteoblast activity in vivo, via a direct Y1 receptor mediated mechanism involving MAPK stimulation evident in vitro. In contrast to PYY knockout mice, PYY over expression also altered bone resorption, as indicated by greater osteoclast surface, despite the lack of Y-receptor expression in osteoclastic cells. While evident in both sexes, cellular changes were generally more pronounced in females.
These data demonstrate that the gut peptide PYY is critical for the control of bone remodeling. This regulatory axis from the intestine to bone has the potential to contribute to the marked bone loss observed in situations of extreme weight loss and higher circulating PYY levels, such as anorexia and bariatric obesity surgery, and may be important in the maintenance of bone mass in the general population.
胃肠道肽越来越多地与控制骨量维持的过程相关联。肽 YY(PYY)是一种源自肠道的神经肽 Y 家族的饱腹感肽,在一些显示低骨量的状态下上调。重要的是,PYY 对 Y 受体具有高亲和力,特别是 Y1R 和 Y2R,它们已知可调节骨量。厌食症和肥胖症的减肥手术会影响 PYY 的循环水平,并对骨量产生负面影响,但这背后的确切机制尚不清楚。因此,我们研究了 PYY 表达的改变是否会影响骨量。
使用组织形态计量学和微计算机断层扫描分析了 PYY 基因敲除和条件性成年 PYY 过表达小鼠在腰椎和股骨部位的骨微结构和细胞活性。
PYY 与成骨细胞活性呈负相关。雄性和雌性 PYY 基因敲除小鼠表现出增强的成骨细胞活性,骨小梁骨量增加。相反,PYY 过表达通过体外 MAPK 刺激证实的直接 Y1 受体介导机制降低了体内成骨细胞活性。与 PYY 基因敲除小鼠不同,PYY 过表达还改变了骨吸收,表现为破骨细胞表面增加,尽管破骨细胞中缺乏 Y 受体表达。虽然在两性中都明显,但细胞变化在女性中通常更为明显。
这些数据表明,肠道肽 PYY 对骨重塑的控制至关重要。这种从肠道到骨骼的调节轴有可能导致在极端体重减轻和更高循环 PYY 水平(如厌食症和减肥肥胖手术)的情况下观察到的明显骨丢失,并可能对一般人群的骨量维持很重要。